Evaluation the Treatment of Nonunion of Long Bone Fracture of Lower Extremities (Femur and Tibia) Using Mononuclear Stem Cells From the Iliac Wing Within a 3-D Tissue Engineered Scaffold

Sponsor
Emdadi Kamyab Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT01958502
Collaborator
National Taiwan University of Science and Technology (Other)
18
1
1
16
1.1

Study Details

Study Description

Brief Summary

Because the rate of non union of long bone in lower extremities specially in tibia in this two last decade due to malnutrition and smoking and other risk factors was increased, so many patient in our country suffer from non union. On the other hand it seems that the use of the mesenchymal stem cells can irritate the union rate. Also for better result we used the mesenchymal stem cells with BMP2 in collagenic scaffold. The collagen has a osteoconductive effect and BMP2 and stem cells has a osteoinductive effect therefore this combination is useful in filling the gap in non union site and irritate the union rate.

Mesenchymal stem cell derived from iliac bone marrow after centrifuge with ficoll procedure. Then the investigators will follow the patient with monthly radiography and evaluate the callus volume and clinical union and any side effect of this treatment. Clinical union consider to relief pain in non union site and be stable in examination.

Condition or Disease Intervention/Treatment Phase
  • Genetic: surgical treatment of non union with mesenchymal stem cells with BMP2 within a 3-D tissue engineered scaffold
Phase 2

Study Design

Study Type:
Interventional
Anticipated Enrollment :
18 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Study Start Date :
Jul 1, 2013
Anticipated Primary Completion Date :
Jul 1, 2014
Anticipated Study Completion Date :
Nov 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Experimental: mesenchymal stem cell

stem cells drived from iliac bone marrow with centrifuge and ficoll method then implant in collagenic 3-D scaffold with BMP-2 and put in non union site by surgical approach under general or spinal anesthesia as deemed appropriate by the anesthetist.

Genetic: surgical treatment of non union with mesenchymal stem cells with BMP2 within a 3-D tissue engineered scaffold

Outcome Measures

Primary Outcome Measures

  1. clinical and radiological union at 1 month to 6 months [6 months]

    patients receiving Mesenchymal Stem Cells within a 3-D tissue engineered scaffold that develop a partial or complete callus at 1, 2, 3, 4 ,5 and 6 months evaluate with standard X-rays

Secondary Outcome Measures

  1. Safety of Mesenchymal Stem Cells injection in nonunion fractures. Follow-up for revealing any significant immediate or late adverse effects(infection,malignancy,local or systemic allergic reaction) [12 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Every patient with non union in the site of long bone fracture

  • Age more than 18 and under 60 years old

  • Fracture having no radiological callus after 6 months and absence of any hypertrophic bone reaction.

  • No infection in site of surgery

  • Be able and willing to participate in the study

  • Written informed consent

Exclusion Criteria:
  • Evidence of malignancy

  • Pregnancy or breastfeeding

  • Patient positive by serology or PCR for HIV, hepatitis B or C infection the patient with Accompanied fracture such as hip fracture that could not weight bearing

Contacts and Locations

Locations

Site City State Country Postal Code
1 Emdai Kamyab Hospital Mashhad Khorasan Iran, Islamic Republic of

Sponsors and Collaborators

  • Emdadi Kamyab Hospital
  • National Taiwan University of Science and Technology

Investigators

  • Principal Investigator: mohammad taghi peivandi, MD, Emdadi Kamyab Hospital
  • Study Director: amin razi, MD, Emdadi Kamyab Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
mohammad taghi peivandi, MD, Emdadi Kamyab Hospital
ClinicalTrials.gov Identifier:
NCT01958502
Other Study ID Numbers:
  • 910359
First Posted:
Oct 9, 2013
Last Update Posted:
Oct 9, 2013
Last Verified:
Oct 1, 2013
Keywords provided by mohammad taghi peivandi, MD, Emdadi Kamyab Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 9, 2013